Active	Status	Sponsor type	Region	Phase	Filter
6 Active 0 Inactive 6 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

6 Trials

Active Trials   

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Ishii, Tomonori
BEconneCTD-ILD, NCT06572384: A Study of the Efficacy and Safety of Belimumab in Adults With Interstitial Lung Disease Associated With Connective Tissue Disease	Recruiting	3	440	Europe, Japan, US, RoW	Belimumab, BENLYSTA, GSK1550188, Placebo	GlaxoSmithKline	Lung Diseases, Interstitial	10/28	12/28
DESTINY, NCT05334368: Depemokimab in Participants With Hypereosinophilic Syndrome, Efficacy, and Safety Trial	Recruiting	3	120	Europe, Canada, Japan, US, RoW	Depemokimab, Placebo	GlaxoSmithKline	Hypereosinophilic Syndrome	02/26	03/26
NCT04781543 / 2020-005764-62: A Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients With Diffuse Cutaneous Systemic Sclerosis Jan 2024 - Dec 2024: Data from trial for diffuse cutaneous systemic sclerosis	Active, not recruiting	2/3	301	Europe, Japan, US, RoW	HZN-825 BID, Placebo, HZN-825 QD	Amgen, Horizon Therapeutics USA, Inc	Diffuse Cutaneous Systemic Sclerosis, Sclerosis, Systemic	09/25	09/25
BLISSc-ILD, NCT05878717: A Study of the Efficacy and Safety of Belimumab in Adults With Systemic Sclerosis Associated Interstitial Lung Disease Jan 2021 - Jun 2021 : Submission in combination with rituximab for SLE	Recruiting	2/3	300	Europe, Japan, US, RoW	Belimumab, BENLYSTA™, GSK1550188, LymphoStat-B™, BENLYSTATM, GSK1550188, LymphoStat-B™, Placebo	GlaxoSmithKline	Systemic Sclerosis Associated Interstitial Lung Disease, Scleroderma, Systemic	07/27	07/27
WILLOW, NCT05162586 / 2021-004648-27: The Study With M5049 in SLE and CLE (SCLE and/or DLE) Oct 2024 - Dec 2024 : Data for SLE Jul 2024 - Sep 2024 : Data for CLE	Completed	2	456	Europe, Japan, US, RoW	Enpatoran low dose, M5049, Enpatoran medium dose, Enpatoran high dose, Placebo	EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany	Systemic Lupus Erythematosus	11/24	11/24
WILLOW LTE, NCT05540327 / 2022-000239-21: The Willow LTE Study With M5049 in Participants With SCLE, DLE and/or SLE	Recruiting	2	532	Europe, Japan, US, RoW	M5049 low dose, Enpatoran, M5049 medium dose, M5049 high dose, Placebo, M5049 very high dose	Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany, Merck Healthcare KGaA	Systemic Lupus Erythematosus	04/25	04/25